Click here to close now.


News Feed Item

Hologic Announces First Quarter Fiscal 2014 Operating Results

BEDFORD, Mass., Feb. 3, 2014 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced its results for the first fiscal quarter ended December 28, 2013.

Highlights of the Quarter Include:

  • Revenues of $612.4 million.
  • Non-GAAP net income of $94.1 million, or $0.34 per diluted share, and adjusted EBITDA (non-GAAP earnings before interest, taxes, depreciation and amortization) of $213.5 million.
  • Net loss of $5.4 million, or $0.02 per diluted share, calculated in accordance with U.S. generally accepted accounting principles (GAAP).
  • Stephen P. MacMillan named President and Chief Executive Officer, and a member of the Board of Directors.
  • FDA approval of the Aptima HPV 16 18/45 genotype assay for use on the Panther system.
  • Voluntary prepayment of an additional $100 million on the Term Loan B facility on October 31, 2013.
  • Redeemed in full $405 million of principal of the 2.00% Convertible Senior Notes issued in 2007.

The following non-GAAP financial measures are included in this press release: revenues, net income, earnings per diluted share (EPS), and adjusted EBITDA. The Company's definitions of these non-GAAP financial measures, and the reconciliations of these measures to the Company's comparable GAAP financial measures for the periods presented, are set forth in the supplemental information attached to this press release. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

First Quarter Fiscal 2014 Operating Results Overview:

First quarter fiscal 2014 revenues decreased 3.0% to $612.4 million from $631.4 million in the prior year (first quarter sales of the prior year included $12.6 million of revenues from Lifecodes, which the Company sold in March 2013). During the same period, non-GAAP revenues decreased 5.0% from $644.6 million. Non-GAAP revenues in the first quarter of fiscal 2013 reflect the addition of $13.3 million primarily related to contingent revenue earned and received under the Company's blood screening collaboration that was eliminated as a result of the effect of purchase accounting.

Fluctuation in foreign currency exchange rates had a negligible impact on revenues compared with the first quarter of fiscal 2013.

First quarter fiscal 2014 net loss was $5.4 million, or $0.02 per diluted share, compared with net income of $3.1 million, or $0.01 per diluted share, for the same period in the prior year. First quarter fiscal 2014 non-GAAP net income was $94.1 million, or $0.34 per diluted share, a decrease of 7.5% and 9.5%, respectively, compared to $101.8 million, or $0.38 per diluted share, in the prior year.

"While we delivered on our commitments in the quarter, we clearly have work to do to return to sustainable top and bottom line growth," said Stephen MacMillan, President and Chief Executive Officer. "Looking forward, I am energized by our unique collection of leading product technologies and a deeply committed and passionate employee base to drive organic growth. Through the balance of fiscal 2014, we will remain focused on improving our operating performance and growth profile and on paying down our debt balance, which we believe will enhance shareholder value."

First Quarter Fiscal 2014 Revenue Overview by Segment (Compared to the First Quarter Fiscal 2013):

  • Diagnostics revenues totaled $285.8 million compared to revenues of $305.9 million in the prior year, a decrease of 6.6%. On a non-GAAP basis, which includes the $13.3 million prior year adjustment described above, sales declined 10.5%. This decline was primarily due to: (i) the Company's divestiture of its Lifecodes business in March 2013, which generated revenues of $12.6 million in the prior year first quarter; (ii) decreases in ThinPrep pap test sales in the U.S. attributed to interval expansion, as well as lower average sales prices internationally; and (iii) a decrease in blood screening revenues, primarily resulting from lower West Nile Virus assay sales. Partially offsetting these declines were increases in molecular product sales from the Company's Aptima product line.
  • Breast Health revenues grew 2.6% to $226.5 million compared to $220.8 million in the prior year. This increase was driven primarily by: increased sales of 3D Dimensions systems as the Company continues to drive a sales shift to 3D Dimensions systems from its 2D systems; service revenue growth of $6.0 million, or 7.5%, from the growing installed base of digital mammography systems; and, to a lesser extent, biopsy device sales growth as a result of market share gains and growth in existing accounts. Partially offsetting these increases was the expected overall sales decline of 2D systems as customers move to the Company's 3D systems. 
  • GYN Surgical revenues totaled $78.9 million compared to $80.9 million in the prior year, a decrease of 2.5%. Significant growth in MyoSure system sales was offset by lower NovaSure system sales. 
  • Skeletal Health revenues totaled $21.3 million compared to $23.7 million in the prior year, a decrease of 10.1%, resulting from decreases in sales of bone densitometry and mini C-arm systems.

Financial Guidance:

The Company's guidance includes current operations, including revenues from its approved and cleared products. This guidance does not include the effects of any future stock repurchases, acquisitions, divestitures or additional voluntary debt payments that may occur during fiscal 2014.

Second Quarter Fiscal 2014 (Quarter Ending March 29, 2014):

  • The Company expects second quarter fiscal 2014 revenues of $605 million to $615 million. Year-over-year, this represents a decrease of 1% to 2% over second quarter fiscal 2013 non-GAAP revenues of $619.1 million (prior year reflects the addition of $6.4 million, primarily relating to a purchase accounting adjustment in the second quarter). The decrease is expected primarily from a decline in sales of ThinPrep pap tests and NovaSure systems, and the elimination of revenues from Lifecodes, which were $10.6 million in the second quarter of fiscal 2013. This decrease is expected to be partially offset by the continued ramp-up of new products including 3D Dimensions, molecular assays, and MyoSure systems.
  • The Company expects non-GAAP EPS of $0.32 to $0.34.

Fiscal 2014 (Year Ending September 27, 2014):

  • The Company is reaffirming fiscal 2014 revenue guidance of $2.425 billion to $2.475 billion. Year-over-year, this represents a decrease of 1% to 3% over fiscal 2013 non-GAAP revenues of $2.51 billion (prior year reflects the addition of $19.7 million primarily relating to a purchase accounting adjustment). The decrease is expected to be primarily a result of a decline in sales of ThinPrep pap tests, blood screening assays, and NovaSure systems, and the elimination of revenues from Lifecodes, which were $23 million in fiscal 2013. This decrease is expected to be partially offset by the continued ramp-up of new products including 3D Dimensions, molecular assays, and MyoSure systems.
  • The Company expects non-GAAP EPS of $1.34 to $1.38 (as compared to $1.32 to $1.38 provided on November 12, 2013). This includes an incremental reduction in EPS from the prior year of $0.02 from the impact of the medical device excise tax and $0.05 from an increase in the expected annual effective tax rate.

Hologic may not generate expected revenues and may incur expenses or charges, realize income or gains, or execute transactions in fiscal 2014 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S., European and general worldwide economic and regulatory conditions and related uncertainties, including the implementation of healthcare cost containment measures and healthcare reform legislation, as well as foreign currency fluctuations, which, along with other uncertainties facing the Company's business including those referenced elsewhere herein and its filings with the Securities and Exchange Commission, could adversely affect anticipated results.

Conference Call and Webcast:

Hologic's management will host a conference call on Monday, February 3, 2014, at 5:00 p.m. (Eastern) to discuss first quarter fiscal year 2014 operating results. Interested participants may listen to the call by dialing 877-397-0292 or 719-325-4942 for international callers and referencing code 6120983 approximately 15 minutes prior to the call. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through Friday, February 21, 2014, at 888-203-1112 or 719-457-0820 for international callers, access code 6120983. The Company will also provide a live webcast of the call. Interested participants may access the webcast on the Company's website at A PowerPoint presentation related to the conference call will be posted to the site.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit

Hologic, Aptima, Dimensions, Gen-Probe, MyoSure, NovaSure, Panther, and ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:

This News Release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herein based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company's strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company's business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ability of the Company to successfully manage recent and ongoing leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees; U.S., European and general worldwide economic conditions and related uncertainties; the Company's reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; uncertainties regarding the recently enacted or future healthcare reform legislation, including associated tax provisions, or budget reduction or other cost containment efforts; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company's products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including without limitation, the Company's ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, the risks that acquisitions may involve unexpected costs or unexpected liabilities, including the risks and challenges associated with the Company's recent acquisition of Gen-Probe and operations in China; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company's international activities and businesses; manufacturing risks, including the Company's reliance on a single or limited source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; the Company's leverage risks, including the Company's obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.




(In thousands)

December 28, 2013

 September 28, 2013



Cash and cash equivalents

$                   448,637

$               829,404

Accounts receivable, net






Prepaid expenses and other current assets



Total current assets



Property and equipment, net



Intangible assets, net






Other assets



$                8,484,308

$            9,000,823



Current portion of long-term debt

$                     77,033

$               563,812

Accounts payable



Accrued expenses



Deferred revenue and other current liabilities



Total current liabilities



Long-term debt, net of current portion



Deferred income taxes and other long-term liabilities



Total long-term liabilities



Total stockholders' equity



$                8,484,308

$            9,000,823



(In thousands, except per share data)

Three Months Ended

December 28, 2013

December 29, 2012


Product sales

$                 512,382

$                 533,254

Service and other revenues






Cost of product sales



Cost of product sales – amortization of intangible assets



Cost of service and other revenues



Research and development



Selling and marketing



General and administrative



Amortization of intangible assets



Contingent consideration



Gain on sale of intellectual property



Restructuring and divestiture charges





Income from operations



Interest expense



Other income



Debt extinguishment loss



Loss before income taxes



Provision (benefit) for income taxes



Net (loss) income

$                   (5,351)

$                     3,118

Net (loss) income per common share:


$                      (0.02)

$                        0.01


$                      (0.02)

$                        0.01

Weighted average number of shares outstanding:







Explanatory Note:    

(1) Stock-based compensation included in costs and expenses during the three months ended December 28, 2013 was $1,510 for cost of revenues, $1,873 for research and development, $1,749 for selling and marketing, $3,833 for general and administrative and $4,761 for restructuring and divestiture. Stock-based compensation included in costs and expenses during the three months ended December 29, 2012 was $1,834 for cost of revenues, $1,868 for research and development, $2,201 for selling and marketing, $5,941 for general and administrative and $222 for restructuring and divestiture.


(In thousands, except earnings per share)

Three Months Ended

December 28, 2013

December 29, 2012


GAAP revenues

$                 612,448

$                  631,362

Adjustment primarily related to blood screening collaboration




Non-GAAP revenues

$                 612,448

$                  644,637


GAAP (loss) earnings per share - Diluted

$                      (0.02)

$                       0.01

Adjustment to net (loss) income (as detailed below)



Non-GAAP earnings per share – Diluted

$                        0.34


$                       0.38



GAAP net (loss) income 

$                     (5,351)

$                      3,118


Amortization of intangible assets





Contingent consideration




Non-cash interest expense relating to convertible notes





Acquisition and integration-related costs





Restructuring and divestiture charges





Fair value adjustment to depreciation expense





Debt extinguishment loss




Fair value write-up of acquired inventory sold




Contingent revenue primarily from blood screening collaboration




Gain on sale of intellectual property




Other charges (gains), net





Income tax effect of reconciling items





Non-GAAP net income

$                     94,148

$                 101,778


Non-GAAP net income

$                    94,148

$                 101,778

Interest expense, net, not adjusted above



Provision for income taxes



Depreciation expense, not adjusted above



Adjusted EBITDA

$                  213,534

$                 227,503

Explanatory Notes:             

(1) To primarily reflect a fair value adjustment relating to contingent revenue earned and received post acquisition under the Company's blood screening collaboration, which was eliminated under purchase accounting.

(2) Non-GAAP earnings per share was calculated based on 275,471 and 269,379 weighted average diluted shares outstanding for the three months ended December 28, 2013 and December 29, 2012, respectively.

(3) To reflect a non-cash charge attributable to the amortization of intangible assets.

(4) To reflect a charge to operating expenses attributable to contingent consideration related to certain of the Company's acquisitions.

(5) To reflect certain non-cash interest expense related to the Company's convertible notes.

(6) To reflect certain costs associated with the Company's acquisition(s) and integration plans, which primarily include retention costs, transfer costs, and asset impairments.

(7) To reflect restructuring and other divestiture charges.

(8) To reflect a non-cash fair value adjustment for additional depreciation expense related to the fair value write-up of fixed assets acquired from Gen-Probe.

(9) To reflect debt extinguishment costs associated with the Company's voluntary $100 million prepayment on the Term Loan B facility.

(10) To reflect a non-cash adjustment recorded for the fair value write-up of inventory acquired from Gen-Probe and sold during the reporting period.

(11) To reflect a net gain resulting from a cash payment received in final settlement of an agreement, net of costs associated with this transaction.

(12) To reflect the net impact from miscellaneous transactions during the period.

(13) To reflect an estimated annual effective tax rate of 34.5% for the three months ended December 28, 2013 and an annual effective tax rate of 32.0% for the three months ended December 29, 2012 on a non-GAAP basis.

Future Non-GAAP Adjustments:

Future GAAP EPS may be affected by changes in ongoing assumptions and judgments relating to the Company's acquired businesses, and may also be affected by nonrecurring, unusual or unanticipated charges, expenses or gains, all of which are excluded in the calculation of non-GAAP EPS as described in this press release. It is therefore not practicable to reconcile non-GAAP EPS guidance to the most comparable GAAP measure. 

Use of Non-GAAP Financial Measures:

The Company has presented the following non-GAAP financial measures in this press release: revenues; net income; EPS; and adjusted EBITDA. The Company defines its non-GAAP revenues to primarily include contingent revenue earned post-acquisition under the blood screening collaboration which was eliminated under purchase accounting. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines its non-GAAP net income and EPS to exclude: (i) the amortization of intangible assets; (ii) acquisition-related charges and effects, such as charges for contingent consideration, transaction costs, integration costs including retention, and credits and/or charges associated with the write-up of acquired inventory and fixed assets to fair value, and the effect of a reduction in revenue primarily related to contingent revenue under the blood screening collaboration, described above; (iii) non-cash interest expense related to amortization of the debt discount for convertible debt securities; (iv) restructuring and divestiture charges; (v) non-cash debt extinguishment losses and related transaction costs; (vi) litigation settlement charges (benefits); (vii) other-than-temporary impairment losses on investments; (viii) other one-time, nonrecurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (ix) income taxes related to such adjustments.

The Company believes the use of non-GAAP revenues is useful to investors as it eliminates certain effects of purchase accounting on its recognition of revenue. The Company believes the use of non-GAAP net income is useful to investors by eliminating certain of the more significant effects of its acquisitions and related activities, non-cash charges resulting from the application of GAAP to convertible debt instruments with cash settlement features, charges related to debt extinguishment losses, investment impairments, litigation settlements, and restructuring and divestiture initiatives. These non-GAAP measures also reflect how Hologic manages its businesses internally. In addition to the adjustments set forth in the calculation of the Company's non-GAAP net income and EPS, its adjusted EBITDA eliminates the effects of financing, income taxes and the accounting effects of capital spending. As with the items eliminated in its calculation of non-GAAP net income, these items may vary for different companies for reasons unrelated to the overall operating performance of a company's business. When analyzing the Company's operating performance, investors should not consider these non-GAAP financial measures as a substitute for net income prepared in accordance with GAAP.

Investor Relations and Media Contacts:

Deborah R. Gordon
Vice President, Investor Relations

(781) 999-7716

[email protected] 

Al Kildani
Senior Director, Investor Relations
(858) 410-8653
[email protected]


SOURCE Hologic, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
The Internet of Things is in the early stages of mainstream deployment but it promises to unlock value and rapidly transform how organizations manage, operationalize, and monetize their assets. IoT is a complex structure of hardware, sensors, applications, analytics and devices that need to be able to communicate geographically and across all functions. Once the data is collected from numerous endpoints, the challenge then becomes converting it into actionable insight.
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
Amazon and Google have built software-defined data centers (SDDCs) that deliver massively scalable services with great efficiency. Yet, building SDDCs has proven to be a near impossibility for ‘normal’ companies without hyper-scale resources. In his session at 17th Cloud Expo, David Cauthron, founder and chief executive officer of Nimboxx, will discuss the evolution of virtualization (hardware, application, memory, storage) and how commodity / open source hyper converged infrastructure (HCI) so...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...